ASP 8477

Drug Profile

ASP 8477

Alternative Names: ASP8477

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class Analgesics
  • Mechanism of Action Central nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 30 Dec 2015 Discontinued - Phase-I for Neuropathic pain in Japan (PO)
  • 30 Oct 2015 Discontinued - Phase-I for Neuropathic pain (In volunteers) in France, Belgium (PO)
  • 30 Oct 2015 Discontinued - Phase-II for Neuropathic pain in United Kingdom, Czech Republic, Poland, Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top